Immunohistochemistry Market Analysis: Growth Drivers and Opportunities

-

The global immunohistochemistry market is projected to reach USD 3.3 billion by 2026 from USD 2.3 billion in 2021, at a CAGR of 7.7% during the forecast period of 2021 to 2026. Market growth is largely driven by the rising geriatric population and subsequent growth in prevalence of chronic and infectious diseases, technological advancements in IHC, and availability of reimbursements for IHC tests. However, the high degree of consolidation in the by the major market players is expected to restrain the growth of this market during the forecast period.

Leading market players

The global immunohistochemistry market is highly competitive. Prominent players operating in the global immunohistochemistry market include F. Hoffman-La Roche AG (Switzerland), Danaher Corporation (US), and Agilent Technologies, Inc. (US). The key players in this market are increasingly focusing on strategic expansions, partnerships, and product launches and approvals to expand their product and geographic footprint and increase market presence.

F. Hoffmann-La Roche AG (Roche) is a global biotechnology company engaged in the development and manufacturing of pharmaceutical and diagnostic products. The company operates through two major divisions or segments, namely, Pharmaceuticals and Diagnostics. The Diagnostics division consists of the four business areas: Centralized and Point of Care Solutions, Molecular Diagnostics, Tissue Diagnostics, and Diabetes Care. The company provides a range of immunohistochemistry products through the Tissue Diagnostics segment. The company has a presence across Europe, the Middle East & Africa, North America, Asia Pacific, and Latin America.

Danaher Corporation is a global science and technology company that designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company operates through three business segments, namely, Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Diagnostics segment provides clinical instrumentation, test consumables, and software to healthcare professionals, and conducts its business through Core Lab Diagnostics, Molecular Diagnostics, Critical Care Diagnostics, and Anatomical Pathology Diagnostics segments. The company offers IHC products through Leica Biosystems, under the Anatomical Pathology Diagnostics and Core Lab Diagnostics segments. Products from these segments include chemical and immuno-staining instruments; reagents; antibodies; consumables; tissue embedding, processing, and slicing instruments; and related reagents and consumables. Slide cover-slipping and slide/cassette marking instruments and imaging instrumentation (including slide scanners) are offered by the company in the field of IHC. The company has its reach in about 60 countries and operates through 261 offices.

Agilent Technologies, Inc. is a leading player in life sciences, diagnostics, and applied chemical markets, providing application-focused solutions that include instruments, software, services, and consumables for the entire laboratory workflow in the fields of food, environmental and forensics, pharmaceutical, diagnostic, chemical & energy, and research. Agilent operates under three business segments—Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Diagnostics and Genomics segment is further segmented into six businesses: Genomics, Nucleic Acid Solutions, Pathology Solutions, Companion Diagnostics, Reagent Partnership, and Biomolecular Analysis. The company offers IHC products through the Pathology Solutions business, focused on cancer diagnostics and anatomic pathology workflows. The company has a presence across North America, Europe, and Asia Pacific. Major countries include the US, the UK, Australia, China, Germany, Italy, Malaysia, Singapore, Belgium, Denmark, Japan, and the Netherlands.

Drivers: The rising geriatric population and subsequent growth in prevalence of chronic and infectious diseases

The increasing geriatric population in developed as well as developing regions will positively influence the growth of the IHC market. With the rapid growth in the geriatric population globally, the prevalence of age-associated diseases is expected to increase significantly. According to the OECD, the number of elderly people living in the US was ~54 million in 2019. Other developed economies around the world also have large and growing geriatric populations. With age, the risk of developing diseases increases proportionately. Thus, the growth in the geriatric population is expected to increase the prevalence of various diseases across the globe. This is considered a key factor driving the growth of the IHC market for diagnostic applications.

Opportunities: Increasing demand for personalized medicine

Personalized medicine for non-small-cell lung cancer patients has proven to be extremely effective, and its use is expected to increase in the future. Immunohistochemistry techniques support this approach to treatment decision-making by performing the most complete and accurate histological subtyping of tumors possible (supported by predictive immunohistochemistry and the assessment of relevant biomarkers). Moreover, the increased availability of immunohistochemistry assays that detect mutant proteins (e.g., BRAF V600E and IDH1 R132H) provides a helpful replacement and/or adjunct for molecular testing. These techniques are highly reproducible, entail reasonable technical and interpretation complexity, and are available at relatively lesser costs, making them valuable novel tools in modern cancer care. The development of multiplex and mutation-specific immunohistochemistry assays represents important innovations, which provide improved utility in the context of personalized medicine and targeted therapy.

Related Links

https://www.marketsandmarkets.com/Market-Reports/immunohistochemistry-market-121632939.html

https://www.marketsandmarkets.com/PressReleases/immunohistochemistry.asp

https://www.marketsandmarkets.com/ResearchInsight/immunohistochemistry-market.asp

Comments

Post a Comment

Popular posts from this blog

Future of Remote Patient Monitoring Industry: Impact of Remote Patient Monitoring on Healthcare

-
Remote patient monitoring is a type of telemedicine technology that enables healthcare providers to monitor their patients’ health remotely. This technology utilizes remote devices that are placed in the patient’s home or worn by the patient to collect medical data such as vital signs and other medical information.  This medical data is then transmitted to the doctor or healthcare provider to help them make better decisions regarding the patient’s care. RPM can be used to monitor a variety of conditions including chronic diseases, mental health issues, and post-operative care. It can also be used to support elderly individuals and those with disabilities. RPM has the potential to improve patient outcomes and reduce healthcare costs by enabling healthcare providers to monitor their patients’ health more effectively. Benefits of Remote Patient Monitoring 1. Increased Patient Engagement: Remote patient monitoring systems provide patients with a convenient way to stay engaged in thei...
Read more

Strategies Adopted by the Major Players in this Digital PCR Market

-
 According to research report the  Digital PCR Market  is expected to grow from USD 3.47 billion in 2017 to USD 5.31 billion by 2022, at a CAGR of 8.9% during the forecast period. Product Launches: Key Strategy Adopted by the Major Players in this Market New product launches and approvals are the key growth strategies adopted by major players to strengthen their position in the global Digital PCR Market. Moreover, strategies such as partnerships, collaborations, and agreements; as well as mergers and acquisitions were also adopted by several market players to strengthen their market position, expand their R&D capabilities, and geographic presence in the global Digital PCR Market. The key players in the Digital PCR Market include Thermo Fisher Scientific, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), Takara Bio, Inc. (Japan), Agilent Technologies, Inc. (US), bioMérieux S.A. (France), Fluid...
Read more

Sinus Dilation Devices Market Size And Share Report, 2027

-
The sinus dilation devices market is on track for significant growth in the coming years, projected to reach USD 3.8 billion by 2027, up from USD 2.8 billion in 2022. This represents a compound annual growth rate (CAGR) of 6.6% during the forecast period. The market's expansion is largely driven by the increasing availability of reimbursements and rising cases of chronic sinusitis. However, the market faces challenges due to the availability of non-surgical treatments for chronic sinusitis and a shortage of skilled ENT surgeons. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=64349810 Key Market Drivers Increasing Availability of Reimbursements: The growing availability of reimbursements for sinus dilation procedures is making them more accessible to patients, thereby driving demand for sinus dilation devices. Rising Incidence of Chronic Sinusitis: The prevalence of chronic sinusitis is on the rise globally, leading to an increase in d...
Read more